#Prophase labs stock license
Under the terms of the license agreement, PBIO has obtained exclusive rights worldwide to develop and commercialize LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms including dementia and Alzheimer’s disease. In preclinical laboratory studies, LB-1 inhibited PIM, which could potentially slow the growth of the cancer and allow for better efficacy of the co-therapy drug or treatment being used. LB-1 is designed as an anti-cancer agent to be used as a co-therapy that targets PIM kinase receptors, a growth factor expressed in cancer.
#Prophase labs stock update
The Company is also making significant progress with a potential strategic partner for ProPhase Precision Medicine, Inc., its wholly owned genomics subsidiary, with plans to update shareholders further in the near future. The Company also announced continued year-over-year quarterly growth in revenues and earnings for Q2 2022 and projected year-over-year growth in Q3 2022. (“Global BioLife”) for the Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications. (“PBIO”), has executed a license agreement with Global BioLife, Inc. (NASDAQ: PRPH), a rapidly growing and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, ProPhase BioPharma, Inc. We then licensed Linebacker 1 and 2, compounds that have multi-billion dollar potential as cancer co-therapies.Garden City, NY, J(GLOBE NEWSWIRE) - ProPhase Labs, Inc.
![prophase labs stock prophase labs stock](https://d1io3yog0oux5.cloudfront.net/_3279074a468602c55a301f1e40b09a4f/prophaselabs/db/1185/9979/social_image_resized.jpg)
Our first licensing efforts included Equivir (OTC) and Equivir G (Rx), broad-based anti-viral compounds. In 2022, we formed ProPhase BioPharma to license, develop and commercialize drugs and compounds with enormous potential.
![prophase labs stock prophase labs stock](https://wallstbusinessnews.com/wp-content/uploads/2021/01/prophase-labs-announces-5-5-million-registered-direct-offering-of-common-stock-and-warrants-1024x1024.jpg)
We are rapidly developing into a true diagnostics and genomics company that will leverage our CLIA laboratories for COVID-19 Testing, whole genome sequencing, and a wide variety of diagnostic testing. In 2021, we acquired Nebula Genomics and formed ProPhase Precision Medicine. In 2020, we pivoted to build out state-of-the-art CLIA labs for COVID-19 diagnostic testing.
![prophase labs stock prophase labs stock](http://www.getfilings.com/sec-filings/121127/ProPhase-Labs-Inc_8-K/image_001.jpg)
Historically, we have been a diversified medical science and technology company that delivers breakthrough, clinically shown supplements, and OTC manufacturing.
![prophase labs stock prophase labs stock](https://ic-cdn.flipboard.com/seekingalpha.com/81d8f8374cecf9a00ea224366d1662d6cebcedcf/_medium.jpeg)
For almost 30 years, ProPhase has been relentlessly focused on enhancing wellness and improving health.